Research ArticleExperimental Studies
Open Access

Therapy-related Myeloid Leukemia With the Translocation t(8;19)(p11;q13) Leading to a KAT6A-LEUTX Fusion Gene

IOANNIS PANAGOPOULOS, KRISTIN ANDERSEN, LLOYD FRODE RAMSLIEN, IDA MÜNSTER IKONOMOU, FRANCESCA MICCI and SVERRE HEIM
Anticancer Research April 2021, 41 (4) 1753-1760; DOI: https://doi.org/10.21873/anticanres.14940

Abstract

Background/Aim: The chromosome translocation t(8;19)(p11;q13) has been reported in only six acute myeloid leukemia (AML) patients. We here present the genetic and clinical features of the seventh AML case with this aberration. Materials and Methods: Cytogenetic and molecular genetic investigations were performed on leukemic bone marrow cells from a patient with therapy-related AML. Results: A t(8;19)(p11;q13) was found leading to an in-frame fusion of exon 16 of the lysine acetyltransferase 6A gene (KAT6A) from 8p11 with exon 2 of the leucine twenty homeobox gene (LEUTX) from 19q13 resulting in expression of the otherwise silent LEUTX gene in the leukemic cells. The KAT6A-LEUTX protein is predicted to act as a histone acetyltransferase at its amino-terminal-KAT6A moiety but as a homeobox transcription factor at the LEUTX-carboxyl-terminal moiety. Conclusion: The present case is the second therapy-related AML, and the third AML overall, in which both a t(8;19)(p11;q13) and its molecular result, a KAT6A-LEUTX fusion gene, are described. The t(8;19)(p11;q13)/KAT6A-LEUTX deregulates transcription and induces leukemogenesis.

Key Words:

The chromosome translocation t(8;19)(p11;q13) was first described in 1988 in an eight-month-old male infant with AML [French-American-British (FAB) classification M5a] in whom the leukemic cells displayed prominent erythrophagocytosis (1). Until now, t(8;19)(p11;q13) has been reported in only six patients with AML and FAB type M5 or M4 (1-7) (Table I). In a therapy-related AML M4 and in a recently reported newborn with AML, the translocation was shown to fuse the lysine acetyltransferase 6A gene (KAT6A, also known as MOZ and MYST3) from 8p11 with the leucine twenty homeobox gene (LEUTX) from 19q13 (1, 2, 5). Because of the rarity of AML carrying a t(8;19)(p11;q13)/KAT6A-LEUTX, we here present the genetic and clinical feature of a therapy-related AML with t(8;19)(p11;q13) and KAT6A-LEUTX fusion.

View this table:
Table I.

The published acute myeloid leukemias (AML) with their French–American–British (FAB) classification carrying a t(8;19)(p11;q13) chromosome translocation.

Materials and Methods

Ethics statement. The study was approved by the regional ethics committee (Regional komité for medisinsk forskningsetikk Sør-Øst, Norge; 2010/1389/REK sør-øst A), and written informed consent was obtained from the patient. All patient information has been anonymized.

Case report. The patient was a seventy-year-old female who had had locally advanced cancer of the uterine cervix for which she had received radiation therapy and cisplatin with curative intent, with cessation of treatment one year prior to the diagnosis of AML. At the time when AML was diagnosed, the patient was suffering from fatigue, dyspnea, headaches, and loss of appetite, functioning in Eastern Cooperative Oncology Group (ECOG) performance status 1. The blood counts and other laboratory analyses showed: Hemoglobin 7.1 g/dl, Leukocytes 0.6×109/l, Neutrophils 0.1×109/l, Lymphocytes 0.5×109/l, Monocytes 0.0×109/l, Eosinophils 0.0×109/l, Basophils 0.0×109/l, Thrombocytes 26×109/l, Creatinine 95 μmol/l, GFR 52, LD 372 U/l, and Ferritin 2010 μg/l. The peripheral blood smear revealed anisocytosis, thrombocytopenia, and neutropenia. There were 2% large myeloblasts. The few neutrophils seen showed no evidence of dysplasia.

The marrow aspirate showed very low cellularity, few megakaryocytes, 3% erythroid precursors, lymphocytes 37%, monocytes 3%, and reduced granulocytopoiesis (20%) with almost all precursors being promyelocytes. The blast cells (33%) were large and cytoplasm rich with vacuoles in both the cytoplasm and nucleus. By flow cytometry, the cells expressed CD45, CD117, dim CD123, CD38, bright CD15, CD33, bright CD64, CD4, and partly myeloperoxidase (MPO), CD36 and HLA-DR, and showed unusually high and variable side scatter signals (SSC). Taken together, the findings were best compatible with AML of monocytic lineage [French-American-British (FAB)-classification M5], probably a therapy-related leukemia according to the WHO classification (8). Because of her prior radiation of the pelvis, no bone marrow biopsy was taken.

Because of her earlier treatment – which included cisplatin as well as radiation of the pelvis - and the very low bone marrow cellularity, the patient was not considered fit for intensive induction therapy, and she was given azacitidin and venetoclax. This treatment did not succeed in inducing remission, although her blood count improved and after two cycles, she became transfusion independent. The treatment has been well tolerated overall, in spite of complications in the form of hemorrhagic cystitis, reduced kidney function, and increased transaminase values that required a reduction of azacitidin and venetoclax doses.

The patient has at the time of writing received 6 courses of azacitidin and venetoclax. Her disease is stable; she has not achieved remission but neither are there signs of progression.

G-banding analysis. Bone marrow cells were short-term cultured and analyzed cytogenetically as previously described (9). Chromosome preparations were made from metaphase cells of a 24-hour culture and G-banded using Leishman stain (Sigma-Aldrich; Merck Millipore, Darmstadt, Germany). Metaphases were analyzed and karyograms prepared using the CytoVision computer-assisted karyotyping system (Leica Biosystems, Newcastle, UK). The karyotypes were written according to the International System for Human Cytogenomic Nomenclature (10).

Molecular genetic analysis. Total RNA was extracted from the patient’s bone marrow at diagnosis using the miRNeasy Mini Kit (Qiagen, Hilden, Germany). Complementary DNA (cDNA) was synthesized from one ng of total RNA using iScript Advanced cDNA Synthesis Kit for RT-qPCR according to the manufacturer’s instructions (Bio-Rad, Hercules, California, USA). The quality of the cDNA synthesis was assessed by amplification of a cDNA fragment of the ABL protooncogene 1, non-receptor tyrosine kinase (ABL1) gene using the primer combination ABL1-91F1/ABL1-404R1 (11).

For amplification of KAT6A-LEUTX cDNA fragments, nested PCR was performed. In the first, outer PCR assay, the 25 μl reaction volume contained 12.5 μl of Premix Taq (Takara Bio Europe/SAS, Saint-Germain-en-Laye, France), 2 μl of cDNA, and 0.4 μM of each of the primers forward KAT6A-3558F1 (5’-TTG AAG ATT CTG ACT CCG AGA GGC-3’) and reverse LEUTX-320R1 (5’-AGG GAG TCT CCT CCT TCT TCA CTG A-3’). PCR amplifications were run on a C-1000 Thermal cycler (Bio-Rad). Cycling included an initial denaturation at 94°C for 30 s followed by 35 cycles of 7 s at 98°C, 30 s at 60°C, and 30 s at 72°C with a final extension for 5 min at 72°C.

Three μl of the PCR products were stained with GelRed (Biotium, Hayward, CA, USA), analyzed by electrophoresis through 1.0% agarose gel, and photographed. DNA gel electrophoresis was performed using lithium borate buffer (12). The remaining 22 μl PCR products were purified using the MinElute PCR purification kit (Qiagen). One μl was used as template in inner, nested PCR amplifications using the forward primer KAT6A-3582F1 (5’-CAA TGC CAA GAT TAG AAC CCA CGT-3’) together with the reverse primer LEUTX-301R1 (5’-ACT GAA GTT GTC TGG TTT GCT GGC-3’) and KAT6A-3582F1 together with LEUTX-157R1 (5’-TTG TAG CCA AAC TTG GGT GCA TG-3’). PCR conditions and cycling were the same as for the first PCR. Three μl of the nested PCR products were analyzed by electrophoresis as described above. The remaining products of nested PCR were purified with the MinElute PCR purification kit (Qiagen) and direct sequenced using the BigDye Terminator v1.1 Cycle Sequencing Kit (ThermoFisher Scientifc) according to the manufacturer’s instructions. Sequence analyses were performed on the Applied Biosystems SeqStudio Genetic Analyzer system (ThermoFisher Scientific). The basic local alignment search tool (BLAST) software was used for computer analysis of sequence data (13). The BLAT alignment tool and the human genome browser at University of California Santa Cruz (UCSC) were used to map the sequences on the Human GRCh37/hg19 assembly (14, 15).

Results

G-banding analysis of bone marrow cells at diagnosis yielded the karyotype 46,XX,t(8;19)(p11.2;q13.3)[10] (Figure 1A). PCR with the primer combination KAT6A-3558F1/LEUTX-320R1 amplified a 477 bp long cDNA fragment (Figure 1B). Nested PCR with the primer combinations KAT6A-3582F1/LEUTX-301R1 and KAT6A-3582F1/LEUTX-157R1 amplified 433 and 288 bp long cDNA fragments, respectively (Figure 1C). Direct sequencing of the nested PCR products showed that both were KAT6A-LEUTX chimeric cDNA fragments in which exon 16 of KAT6A (nucleotide 3764 in sequence with accession number NM_006766.5) was fused in frame to exon 2 of LEUTX (nucleotide 75 in sequence with accession number NM_001382345.1) (Figure 1D).

Figure 1.
Figure 1.

Examination by G-banding analysis, reverse transcription polymerase chain reaction (RT-PCR), and Sanger sequencing of the therapy-related acute myeloid leukemia (AML). A) Karyogram showing the der(8)t(8;19)(p11.2;q13.3) and der(19)t(8;19)(p11.2;q13.3). Breakpoints are indicated by arrows. B) Gel electrophoresis showing the amplified KAT6A-LEUTX cDNA fragments using the outer primer combination KAT6A-3558F1/LEUTX-320R1 (lane 1) and the amplified control ABL1 cDNA fragment using the ABL1-91F1/ABL1-404R1 primer combination (lane 2). C) Gel electrophoresis showing the amplified KAT6A-LEUTX cDNA fragments with nested PCR using the primer combinations KAT6A-3582F1/LEUTX-301R1 (lane 1) and KAT6A-3582F1/LEUTX-157R1 (lane 2). M: GeneRuler 1 Kb Plus DNA ladder (ThermoFisher Scientific). D) Partial sequence chromatograms of the cDNA amplified fragment showing the junction between exons 16 of KAT6A and 2 of LEUTX.

Discussion

To the best of our knowledge, the present case is the second therapy-related AML and the third AML overall in which both the translocation t(8;19)(p11;q13) and the resulting KAT6A-LEUTX fusion are reported [(2, 5), present study]. All three AMLs have the same fusion transcript in which exon 16 of KAT6A (nucleotide 3764 in sequence with accession number NM_006766.5) is fused in frame to exon 2 of LEUTX (nucleotide 75 in sequence with accession number NM_001382345.1).

The KAT6A gene together with its paralog KAT6B on 10q22 (also known as MORF, MOZ2, and MYST4), KAT5 on 11q13 (also known as TIP60), KAT7 on 17q21 (also known as HBO1 and MYST2), and KAT8 on 16p11 (also known as MOF and MYST1) code for proteins that compose the MYST family of histone acetyltransferases (16-18). These proteins share a highly conserved MYST domain consisting of the Acetyl-CoA-binding motif and a plant homeodomain (PHD)-type zinc finger domain (17-20). KAT6A and KAT6B acetyltransferases acylate both histone H3 and non-histone proteins, play important roles in many cellular activities, such as regulation of transcription, signal transduction, chromatin organization and cell differentiation, and regulate various biological processes such as hematopoiesis, neurogenesis, skeletogenesis, and craniofacial as well as heart development (17, 21, 22).

The first 810 amino acids of the KAT6A protein contain a nuclear localization domain, two PHD zinc finger domains, a histone acetyl-transferase domain, regions which interact with the proteins runt-related transcription factor 1 (RUNX1), promyelocytic leukemia protein (PML) and bromodomain and PHD finger containing 1 (BRPF1), and many phosphorylation and acetylation sites (Figure 2). The other part of the KAT6A protein (amino acids 1001-2004) contains a region which interacts with both RUNX1 and PML proteins and a region which is required for activation of RUNX1 (Figure 2) (see reference sequence NP_006757.2; https://www.ncbi.nlm.nih.gov/protein/NP_006757.2).

Figure 2.
Figure 2.

The proteins histone lysine acetyltransferase 6A (KAT6A) isoform 1(accession number NP_006757.2) and leucine twenty homeobox (LEUTX) isoform 1 (accession number NP_001369274.1). All known regions and sites are shown. Vertical dotted lines show the breakpoints in the various translocations.

LEUTX is a paired (PRD)-like homeobox protein implicated in embryogenesis. Its expression is restricted to the 4-cell to 8-cell stage of the preimplantation embryo where it is one of the regulators of embryonic genome activation (23-25). LEUTX is not expressed in any other cell type including human embryonic stem cells (24, 25). It has three sites, which are required for binding to the 5’-TAATCC-3’ sequence, and four nine-amino-acid transactivation domains (9aaTAD) (see reference sequence NP_001369274.1; https://www.ncbi.nlm.nih.gov/protein/NP_001369274.1).

A major consequence of t(8;19)(p11;q13) is expression of the LEUTX gene in the leukemic cells. The ensuing 1313 amino acids long KAT6A-LEUTX chimeric protein is composed of the first 1117 amino acids from KAT6A (reference sequence NP_006757.2) and almost the entire LEUTX protein (reference sequence NP_001369274.1; only the first two amino acids were missing). KAT6A-LEUTX is predicted to have a dual function: its KAT6A amino-terminal part acylates both histone H3 and non-histone proteins, whereas its LEUTX carboxy-terminal part binds to a 36 bp DNA element containing a 5’-TAATCC-3’ sequence motif in the promoters of the target gene and, through the four 9aaTAD, activates transcription (22, 24-26). Abnormal expression of homeobox genes has been reported in various types of neoplasia including leukemias (27-32). Ectopic expression of the caudal-type homeobox gene CDX2 or expression of various NUP98-HOX fusion genes has induced AML in mice (33, 34). Thus, the involvement of the KAT6A-LEUTX fusion gene in leukemogenesis seems well established.

Apart from the KAT6A-LEUTX fusion, KAT6A is known to fuse, as a 5’-end partner, to the CREB binding protein (CREBBP) gene and E1A binding protein p300 gene (EP300) in AML carrying the chromosome translocations t(8;16)(p11;p13) and t(8;22)(p11;q13), respectively (35-38). CREBBP and EP300 are lysine acetyltransferases with many cellular functions (39, 40). In addition, KAT6A also fuses, again as a 5’-end fusion partner, with the nuclear receptor coactivator 2 (NCOA2) and nuclear receptor coactivator 3 (NCOA3) genes in AML with inv(8)(p11q13) and t(8;20)(p11;q13), respectively (41-44). The proteins NCOA2 and NCOA3 are members of the p160/steroid receptor coactivator family that mediate the transcriptional functions of nuclear receptors and other transcription factors (45-47). In a pediatric therapy-related myelodysplastic syndrome with t(2;8)(p23;p11), KAT6A was fused to the ASXL transcriptional regulator 2 gene (ASXL2), which codes for a protein member of additional sex combs-like protein (ASXL) family (48-50) (for KAT6A-ASXL2 fusion, see sequences with accession numbers AB084281.1 and BAD00088.1 in the National Center for Biotechnology Information database). The members of the ASXL family are epigenetic scaffolding proteins that assemble epigenetic regulators and transcription factors to specific genomic loci with histone modifications (51-53). In a similar way to KAT6A-LEUTX, all the above-mentioned chimeric proteins retain the amino-terminal-KAT6A moiety, which contains the nuclear localization signal, two PHD zinc fingers, and the histone acetyl-transferase domain, the regions which interact with RUNX1, PML, and BRPF1 proteins, as well as the phosphorylation and acetylation sites. They lack the carboxyl terminal moiety of KAT6A, which interacts with RUNX1 and PML proteins, and also a region which is required for activation of RUNX1 (Figure 2).

Thus, a chimeric protein containing an amino-terminal part acylating both histone H3 and non-histone proteins, and a carboxy terminal regulating transcription, come across as a common theme whenever KAT6A-fusion genes occur in hematologic malignancies.

Acknowledgements

This work was supported by grants from Radiumhospitalets Legater.

Footnotes

  • Authors’ Contributions

    IP designed and supervised the experiments, performed molecular genetic experiments, evaluated the data, and drafted the manuscript. KA performed cytogenetic and molecular experiments, and evaluated the data. LFR made clinical evaluations and treated the patient. IMI performed diagnostic flow cytometry. FM evaluated the cytogenetic data. SH evaluated the data and assisted with writing of the manuscript. All Authors read and approved the final manuscript.

  • This article is freely accessible online.

  • Conflicts of Interest

    The Authors declare that they have no potential conflicts of interest in this study.

  • Received February 3, 2021.
  • Revision received February 22, 2021.
  • Accepted February 23, 2021.

This is an open access article distributed under the CC BY license (https://creativecommons.org/licenses/by/4.0/).

References

  1. ↵
    1. Brizard A,
    2. Guilhot F,
    3. Huret JL,
    4. Benz-Lemoine E and
    5. Tanzer J
    : The 8p11 anomaly in “monoblastic” leukaemia. Leuk Res 12(8): 693-697, 1988. PMID: 3184987. DOI: 10.1016/0145-2126(88)90105-1
    OpenUrlCrossRefPubMed
  2. ↵
    1. Chinen Y,
    2. Taki T,
    3. Tsutsumi Y,
    4. Kobayashi S,
    5. Matsumoto Y,
    6. Sakamoto N,
    7. Kuroda J,
    8. Horiike S,
    9. Nishida K,
    10. Ohno H,
    11. Uike N and
    12. Taniwaki M
    : The leucine twenty homeobox (LEUTX) gene, which lacks a histone acetyltransferase domain, is fused to KAT6A in therapy-related acute myeloid leukemia with t(8;19)(p11;q13). Genes Chromosomes Cancer 53(4): 299-308, 2014. PMID: 24446090. DOI: 10.1002/gcc.22140
    OpenUrlCrossRefPubMed
    1. Eason AC,
    2. Bunting ST,
    3. Peterson JF,
    4. Saxe D and
    5. Sabnis HS
    : Acute myeloid leukemia in an infant with t(8;19)(p11.2;q13) translocation: Case report and a review of the literature. Case Rep Hematol 2019: 4198415, 2019. PMID: 31583141. DOI: 10.1155/2019/4198415
    OpenUrlCrossRef
    1. Gervais C,
    2. Murati A,
    3. Helias C,
    4. Struski S,
    5. Eischen A,
    6. Lippert E,
    7. Tigaud I,
    8. Penther D,
    9. Bastard C,
    10. Mugneret F,
    11. Poppe B,
    12. Speleman F,
    13. Talmant P,
    14. VanDen Akker J,
    15. Baranger L,
    16. Barin C,
    17. Luquet I,
    18. Nadal N,
    19. Nguyen-Khac F,
    20. Maarek O,
    21. Herens C,
    22. Sainty D,
    23. Flandrin G,
    24. Birnbaum D,
    25. Mozziconacci MJ,
    26. Lessard M and Groupe Francophone de Cytogénétique Hématologique
    .: Acute myeloid leukaemia with 8p11 (MYST3) rearrangement: An integrated cytologic, cytogenetic and molecular study by the groupe francophone de cytogénétique hématologique. Leukemia 22(8): 1567-1575, 2008. PMID: 18528428. DOI: 10.1038/leu.2008.128
    OpenUrlCrossRefPubMed
  5. ↵
    1. Sramkova L,
    2. Cermakova J,
    3. Kutkova K,
    4. Zemanova Z,
    5. Pavlicek P,
    6. Zuna J,
    7. Stary J and
    8. Zaliova M
    : Rapidly progressing acute myeloid leukemia with KAT6A-LEUTX fusion in a newborn. Pediatr Blood Cancer 67(10): e28663, 2020. PMID: 32779858. DOI: 10.1002/pbc.28663
    OpenUrlCrossRef
    1. Stark B,
    2. Resnitzky P,
    3. Jeison M,
    4. Luria D,
    5. Blau O,
    6. Avigad S,
    7. Shaft D,
    8. Kodman Y,
    9. Gobuzov R and
    10. Ash S
    : A distinct subtype of M4/M5 acute myeloblastic leukemia (AML) associated with t(8:16)(p11:p13), in a patient with the variant t(8:19)(p11:q13) – case report and review of the literature. Leuk Res 19(6): 367-379, 1995. PMID: 7596149. DOI: 10.1016/0145-2126(94)00150-9
    OpenUrlCrossRefPubMed
  7. ↵
    1. Tanzer J,
    2. Brizard A,
    3. Guilhot F,
    4. Benz-Lemoine E,
    5. Dreyfus B,
    6. Lessard M,
    7. Herchkovitch C,
    8. Mossafa H,
    9. Davi F and
    10. Huret J
    : [Acute leukemia with translocation (8;16)]. Nouv Rev Fr Hematol 30(1-2): 83-87, 1988. PMID: 3290841.
    OpenUrl
  8. ↵
    1. Swerdlow SH,
    2. Campo E,
    3. Harris NL,
    4. Jaffe ES,
    5. Pileri SA,
    6. Stein H and
    7. Thiele J
    : WHO classification of tumours of haematopoietic and lymphoid tissues (Revised 4th edition). lARC: Lyon, 2017.
  9. ↵
    1. Rooney DE
    1. Czepulkowski B
    : Basic techniques for the preparation and analysis of chromosomes from bone marrow and leukaemic blood. In: Human cytogenetics: malignancy and acquired abnormalities. Rooney DE (ed.). Oxford University Press: New York, pp. 1-26, 2001.
  10. ↵
    1. McGowan-Jordan J,
    2. Simons A and
    3. Schmid M
    : ISCN 2016: An international system for human cytogenomic nomenclature Karger: Basel, pp. 140, 2016.
  11. ↵
    1. Torkildsen S,
    2. Brunetti M,
    3. Gorunova L,
    4. Spetalen S,
    5. Beiske K,
    6. Heim S and
    7. Panagopoulos I
    : Rearrangement of the chromatin organizer special at-rich binding protein 1 gene, SATB1, resulting from a t(3;5)(p24;q14) chromosomal translocation in acute myeloid leukemia. Anticancer Res 37(2): 693-698, 2017. PMID: 28179318. DOI: 10.21873/anticanres.11365
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Singhal H,
    2. Ren YR and
    3. Kern SE
    : Improved DNA electrophoresis in conditions favoring polyborates and lewis acid complexation. PLoS One 5(6): e11318, 2010. PMID: 20593002. DOI: 10.1371/journal.pone.0011318
    OpenUrlCrossRefPubMed
  13. ↵
    1. Altschul SF,
    2. Gish W,
    3. Miller W,
    4. Myers EW and
    5. Lipman DJ
    : Basic local alignment search tool. J Mol Biol 215(3): 403-410, 1990. PMID: 2231712. DOI: 10.1016/S0022-2836(05)80360-2
    OpenUrlCrossRefPubMed
  14. ↵
    1. Kent WJ
    : BLAT – the BLAST-like alignment tool. Genome Res 12(4): 656-664, 2002. PMID: 11932250. DOI: 10.1101/gr.229202
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Kent WJ,
    2. Sugnet CW,
    3. Furey TS,
    4. Roskin KM,
    5. Pringle TH,
    6. Zahler AM and
    7. Haussler D
    : The human genome browser at UCSC. Genome Res 12(6): 996-1006, 2002. PMID: 12045153. DOI: 10.1101/gr.229102
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Avvakumov N and
    2. Côté J
    : The MYST family of histone acetyltransferases and their intimate links to cancer. Oncogene 26(37): 5395-5407, 2007. PMID: 17694081. DOI: 10.1038/sj.onc.1210608
    OpenUrlCrossRefPubMed
  17. ↵
    1. Sapountzi V and
    2. Côté J
    : MYST-family histone acetyltransferases: beyond chromatin. Cell Mol Life Sci 68(7): 1147-1156, 2011. PMID: 21132344. DOI: 10.1007/s00018-010-0599-9
    OpenUrlCrossRefPubMed
  18. ↵
    1. Utley RT and
    2. Côté J
    : The MYST family of histone acetyltransferases. Curr Top Microbiol Immunol 274: 203-236, 2003. PMID: 12596909. DOI: 10.1007/978-3-642-55747-7_8
    OpenUrlCrossRefPubMed
  19. ↵
    1. Avvakumov N and
    2. Côté J
    : Functions of myst family histone acetyltransferases and their link to disease. Subcell Biochem 41: 295-317, 2007. PMID: 17484133
    OpenUrlPubMed
  20. ↵
    1. Thomas T and
    2. Voss AK
    : The diverse biological roles of MYST histone acetyltransferase family proteins. Cell Cycle 6(6): 696-704, 2007. PMID: 17374998. DOI: 10.4161/cc.6.6.4013
    OpenUrlCrossRefPubMed
  21. ↵
    1. Perez-Campo FM,
    2. Costa G,
    3. Lie-a-Ling M,
    4. Kouskoff V and
    5. Lacaud G
    : The MYSTerious MOZ, a histone acetyltransferase with a key role in haematopoiesis. Immunology 139(2): 161-165, 2013. PMID: 23347099. DOI: 10.1111/imm.12072
    OpenUrlCrossRefPubMed
  22. ↵
    1. Wiesel-Motiuk N and
    2. Assaraf YG
    : The key roles of the lysine acetyltransferases KAT6A and KAT6B in physiology and pathology. Drug Resist Updat 53: 100729, 2020. PMID: 33130515. DOI: 10.1016/j.drup.2020.100729
    OpenUrlCrossRef
  23. ↵
    1. Töhönen V,
    2. Katayama S,
    3. Vesterlund L,
    4. Jouhilahti EM,
    5. Sheikhi M,
    6. Madissoon E,
    7. Filippini-Cattaneo G,
    8. Jaconi M,
    9. Johnsson A,
    10. Bürglin TR,
    11. Linnarsson S,
    12. Hovatta O and
    13. Kere J
    : Novel PRD-like homeodomain transcription factors and retrotransposon elements in early human development. Nat Commun 6: 8207, 2015. PMID: 26360614. DOI: 10.1038/ncomms9207
    OpenUrlCrossRefPubMed
  24. ↵
    1. Jouhilahti EM,
    2. Madissoon E,
    3. Vesterlund L,
    4. Töhönen V,
    5. Krjutškov K,
    6. Plaza Reyes A,
    7. Petropoulos S,
    8. Månsson R,
    9. Linnarsson S,
    10. Bürglin T,
    11. Lanner F,
    12. Hovatta O,
    13. Katayama S and
    14. Kere J
    : The human PRD-like homeobox gene LEUTX has a central role in embryo genome activation. Development 143(19): 3459-3469, 2016. PMID: 27578796. DOI: 10.1242/dev.134510
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Katayama S,
    2. Ranga V,
    3. Jouhilahti EM,
    4. Airenne TT,
    5. Johnson MS,
    6. Mukherjee K,
    7. Bürglin TR and
    8. Kere J
    : Phylogenetic and mutational analyses of human LEUTX, a homeobox gene implicated in embryogenesis. Sci Rep 8(1): 17421, 2018. PMID: 30479355. DOI: 10.1038/s41598-018-35547-5
    OpenUrlCrossRef
  26. ↵
    1. Yang XJ
    : MOZ and MORF acetyltransferases: Molecular interaction, animal development and human disease. Biochim Biophys Acta 1853(8): 1818-1826, 2015. PMID: 25920810. DOI: 10.1016/j.bbamcr.2015.04.014
    OpenUrlCrossRef
  27. ↵
    1. Rawat VP,
    2. Humphries RK and
    3. Buske C
    : Beyond Hox: The role of ParaHox genes in normal and malignant hematopoiesis. Blood 120(3): 519-527, 2012. PMID: 22547580. DOI: 10.1182/blood-2012-02-385898
    OpenUrlAbstract/FREE Full Text
    1. Alharbi RA,
    2. Pettengell R,
    3. Pandha HS and
    4. Morgan R
    : The role of HOX genes in normal hematopoiesis and acute leukemia. Leukemia 27(5): 1000-1008, 2013. PMID: 23212154. DOI: 10.1038/leu.2012.356
    OpenUrlCrossRefPubMed
    1. Bhatlekar S,
    2. Fields JZ and
    3. Boman BM
    : HOX genes and their role in the development of human cancers. J Mol Med (Berl) 92(8): 811-823, 2014. PMID: 24996520. DOI: 10.1007/s00109-014-1181-y
    OpenUrlCrossRefPubMed
    1. De Braekeleer E,
    2. Douet-Guilbert N,
    3. Basinko A,
    4. Le Bris MJ,
    5. Morel F and
    6. De Braekeleer M
    : Hox gene dysregulation in acute myeloid leukemia. Future Oncol 10(3): 475-495, 2014. PMID: 24559452. DOI: 10.2217/fon.13.195
    OpenUrlCrossRef
    1. Collins EM and
    2. Thompson A
    : HOX genes in normal, engineered and malignant hematopoiesis. Int J Dev Biol 62(11-12): 847-856, 2018. PMID: 30604854. DOI: 10.1387/ijdb.180206at
    OpenUrlCrossRef
  32. ↵
    1. Nagel S and
    2. Drexler HG
    : Deregulated NKL homeobox genes in B-cell lymphoma. Cancers (Basel) 11(12): 2019. PMID: 31779217. DOI: 10.3390/cancers11121874
    OpenUrlCrossRef
  33. ↵
    1. Rawat VP,
    2. Cusan M,
    3. Deshpande A,
    4. Hiddemann W,
    5. Quintanilla-Martinez L,
    6. Humphries RK,
    7. Bohlander SK,
    8. Feuring-Buske M and
    9. Buske C
    : Ectopic expression of the homeobox gene Cdx2 is the transforming event in a mouse model of t(12;13)(p13;q12) acute myeloid leukemia. Proc Natl Acad Sci USA 101(3): 817-822, 2004. PMID: 14718672. DOI: 10.1073/pnas.0305555101
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. Gough SM,
    2. Slape CI and
    3. Aplan PD
    : NUP98 gene fusions and hematopoietic malignancies: Common themes and new biologic insights. Blood 118(24): 6247-6257, 2011. PMID: 21948299. DOI: 10.1182/blood-2011-07-328880
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Borrow J,
    2. Stanton VP Jr.,
    3. Andresen JM,
    4. Becher R,
    5. Behm FG,
    6. Chaganti RS,
    7. Civin CI,
    8. Disteche C,
    9. Dubé I,
    10. Frischauf AM,
    11. Horsman D,
    12. Mitelman F,
    13. Volinia S,
    14. Watmore AE and
    15. Housman DE
    : The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet 14(1): 33-41, 1996. PMID: 8782817. DOI: 10.1038/ng0996-33
    OpenUrlCrossRefPubMed
    1. Panagopoulos I,
    2. Isaksson M,
    3. Lindvall C,
    4. Björkholm M,
    5. Ahlgren T,
    6. Fioretos T,
    7. Heim S,
    8. Mitelman F and
    9. Johansson B
    : RT-PCR analysis of the MOZ-CBP and CBP-MOZ chimeric transcripts in acute myeloid leukemias with t(8;16)(p11;p13). Genes Chromosomes Cancer 28(4): 415-424, 2000. PMID: 10862050. DOI: 10.1002/1098-2264(200008)28:4<415::aid-gcc7>3.0.co;2-i
    OpenUrlCrossRefPubMed
    1. Chaffanet M,
    2. Gressin L,
    3. Preudhomme C,
    4. Soenen-Cornu V,
    5. Birnbaum D and
    6. Pébusque MJ
    : MOZ is fused to p300 in an acute monocytic leukemia with t(8;22). Genes Chromosomes Cancer 28(2): 138-144, 2000. PMID: 10824998. DOI: 10.1002/(sici)1098-2264(200006)28:2<138::aid-gcc2>3.0.co;2-2
    OpenUrlCrossRefPubMed
  38. ↵
    1. Kitabayashi I,
    2. Aikawa Y,
    3. Yokoyama A,
    4. Hosoda F,
    5. Nagai M,
    6. Kakazu N,
    7. Abe T and
    8. Ohki M
    : Fusion of MOZ and p300 histone acetyltransferases in acute monocytic leukemia with a t(8;22)(p11;q13) chromosome translocation. Leukemia 15(1): 89-94, 2001. PMID: 11243405. DOI: 10.1038/sj.leu.2401983
    OpenUrlCrossRefPubMed
  39. ↵
    1. Dancy BM and
    2. Cole PA
    : Protein lysine acetylation by p300/CBP. Chem Rev 115(6): 2419-2452, 2015. PMID: 25594381. DOI: 10.1021/cr500452k
    OpenUrlCrossRefPubMed
  40. ↵
    1. Attar N and
    2. Kurdistani SK
    : Exploitation of EP300 and CREBBP lysine acetyltransferases by cancer. Cold Spring Harb Perspect Med 7(3): 2017. PMID: 27881443. DOI: 10.1101/cshperspect.a026534
    OpenUrlAbstract/FREE Full Text
  41. ↵
    1. Liang J,
    2. Prouty L,
    3. Williams BJ,
    4. Dayton MA and
    5. Blanchard KL
    : Acute mixed lineage leukemia with an inv(8)(p11q13) resulting in fusion of the genes for MOZ and TIF2. Blood 92(6): 2118-2122, 1998. PMID: 9731070.
    OpenUrlAbstract/FREE Full Text
    1. Carapeti M,
    2. Aguiar RC,
    3. Goldman JM and
    4. Cross NC
    : A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia. Blood 91(9): 3127-3133, 1998. PMID: 9558366.
    OpenUrlAbstract/FREE Full Text
    1. Carapeti M,
    2. Aguiar RC,
    3. Watmore AE,
    4. Goldman JM and
    5. Cross NC
    : Consistent fusion of MOZ and TIF2 in AML with inv(8)(p11q13). Cancer Genet Cytogenet 113(1): 70-72, 1999. PMID: 10459350. DOI: 10.1016/s0165-4608(99)00007-2
    OpenUrlCrossRefPubMed
  44. ↵
    1. Esteyries S,
    2. Perot C,
    3. Adelaide J,
    4. Imbert M,
    5. Lagarde A,
    6. Pautas C,
    7. Olschwang S,
    8. Birnbaum D,
    9. Chaffanet M and
    10. Mozziconacci MJ
    : NCOA3, a new fusion partner for MOZ/MYST3 in M5 acute myeloid leukemia. Leukemia 22(3): 663-665, 2008. PMID: 17805331. DOI: 10.1038/sj.leu.2404930
    OpenUrlCrossRefPubMed
  45. ↵
    1. York B and
    2. O’Malley BW
    : Steroid receptor coactivator (SRC) family: Masters of systems biology. J Biol Chem 285(50): 38743-38750, 2010. PMID: 20956538. DOI: 10.1074/jbc.R110.193367
    OpenUrlAbstract/FREE Full Text
    1. Dasgupta S,
    2. Lonard DM and
    3. O’Malley BW
    : Nuclear receptor coactivators: Master regulators of human health and disease. Annu Rev Med 65: 279-292, 2014. PMID: 24111892. DOI: 10.1146/annurev-med-051812-145316
    OpenUrlCrossRefPubMed
  47. ↵
    1. Szwarc MM,
    2. Kommagani R,
    3. Lessey BA and
    4. Lydon JP
    : The p160/steroid receptor coactivator family: potent arbiters of uterine physiology and dysfunction. Biol Reprod 91(5): 122, 2014. PMID: 25297546. DOI: 10.1095/biolreprod.114.125021
    OpenUrlCrossRefPubMed
  48. ↵
    1. Imamura T,
    2. Kakazu N,
    3. Hibi S,
    4. Morimoto A,
    5. Fukushima Y,
    6. Ijuin I,
    7. Hada S,
    8. Kitabayashi I,
    9. Abe T and
    10. Imashuku S
    : Rearrangement of the MOZ gene in pediatric therapy-related myelodysplastic syndrome with a novel chromosomal translocation t(2;8)(p23;p11). Genes Chromosomes Cancer 36(4): 413-419, 2003. PMID: 12619166. DOI: 10.1002/gcc.10172
    OpenUrlCrossRefPubMed
    1. Katoh M and
    2. Katoh M
    : Identification and characterization of ASXL2 gene in silico. Int J Oncol 23(3): 845-850, 2003. PMID: 12888926
    OpenUrlPubMed
  50. ↵
    1. Katoh M and
    2. Katoh M
    : Identification and characterization of ASXL3 gene in silico. Int J Oncol 24(6): 1617-1622, 2004. PMID: 15138607.
    OpenUrlPubMed
  51. ↵
    1. Katoh M
    : Functional and cancer genomics of ASXL family members. Br J Cancer 109(2): 299-306, 2013. PMID: 23736028. DOI: 10.1038/bjc.2013.281
    OpenUrlCrossRefPubMed
    1. Russell B and
    2. Graham JM Jr.
    : Expanding our knowledge of conditions associated with the ASXL gene family. Genome Med 5(2): 16, 2013. PMID: 23672984. DOI: 10.1186/gm420
    OpenUrlCrossRefPubMed
  53. ↵
    1. Micol JB and
    2. Abdel-Wahab O
    : The role of additional sex combs-like proteins in cancer. Cold Spring Harb Perspect Med 6(10): 2016. PMID: 27527698. DOI: 10.1101/cshperspect.a026526
    OpenUrlCrossRef
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Therapy-related Myeloid Leukemia With the Translocation t(8;19)(p11;q13) Leading to a KAT6A-LEUTX Fusion Gene
IOANNIS PANAGOPOULOS, KRISTIN ANDERSEN, LLOYD FRODE RAMSLIEN, IDA MÜNSTER IKONOMOU, FRANCESCA MICCI, SVERRE HEIM
Anticancer Research Apr 2021, 41 (4) 1753-1760; DOI: 10.21873/anticanres.14940
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo

Jump to section

Keywords